Manufacturing

FDA's approval will allow Kedrion to manufacture Ryplazim (plasminogen, human-tvmh), the only FDA-approved therapy for treating PLGD-1, at facility in Bolognana, Italy.

The Thousand Oaks, Calif., cell therapy manufacturing facility now houses new production suites, updated development labs, and more after expansion.

The $3.6 million investment will allow the CDMO to boost its advanced labeling, automated visual inspection, and fill/finish capabilities.

Sanofi will use this investment to increase its antibody bioproduction at its site in Lyon Gerland, France.

Webinar Date/Time: Thu, Dec 5, 2024 11:00 AM EST

The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.

Located in German, Italy, and Lithuania, the new European facilities will specialize in drug discovery and R&D services.

SEKISUI has used a £15.7 million (US$20.7 million) investment to expand its clinical-grade drug substance manufacturing at its UK site.

Financing from OrbiMed, Novo Holdings, Jeito Capital, and others will enable Alentis Therapeutics to advance its pipeline of Claudin-1-targeted ADCs for treating solid tumors.

Frontier Scientific Solutions has unveiled plans to use a $1.5 billion commitment from a major investor to create a global free trade zone gateway to facilitate the life sciences supply chain using Wilmington International Airport in North Carolina.

Avantor's newly launched expanded Innovation Center in Bridgewater, NJ, is designed for integrated workflows and features purpose-built collaboration spaces.

Executives at Avantor talk about the future of the biopharmaceutical industry and the anticipated impact that a wave of next-generation biotherapeutics will bring.

Brian Feth and Jonathan Grinstein go behind the headlines to discuss the impact of a Republican administration on Federal Trade Commission actions, tax relief, and Health and Human Services (HHS) leadership; as well as advancements in CAR-T.

Under an ongoing partnership with Merck, known as MSD outside of the United States and Canada, Ginkgo Bioworks has achieved the first milestone in a project aimed at improving biologics production.

Manufacturers of five autologous or matched allogenic cell therapy products have selected TrakCel's IT platform, OCELLOS, to orchestrate the administration of these therapies, which are approved or expected to be approved in 2024.

Ascend is partnering with EW Healthcare Partners to expand capabilities in the United States.

Evolving industry demands are driving the need for greater flexibility and innovation in processing equipment for pharmaceutical manufacturing.

The companies will work to create climate-friendly pMDIs using Orbia’s low global warming potential propellant.

Pharmaceutical training programs are enhanced by integrating ICH quality risk management considerations.

Synaffix, a Lonza company, has licensed its ADC technology to BigHat Biosciences to be combined with the latter's ML design platform to develop new ADCs

Shifting to automated, closed modular manufacturing systems is growing increasingly crucial for biopharmaceutical production.

Capturing and curating R&D data are crucial to realizing the full value of advanced analytics.

The complexities of tech transfer may be overcome by data-driven approaches, digital tools, and effective communication.

Recent hurricanes in the US close Baxter plant, shining a spotlight on supply chain fragility again.

The ROSS FDA-50 Fixed Tank Dual Shaft Mixer is built to handle a wide range of formulations and viscosities and is ideal for processes that require meticulous control over mixing, temperature, and pressure.

The Mobius ADC Reactor is the first single-use reactor designed specifically for the manufacture of antibody drug conjugates.

CPC’s MicroCNX ULT Series represents the first aseptic microconnector that can be fitted directly into freeze cassettes for GCT production.

With DKK 600 million (US$87.4 million) in funding from the Novo Nordisk Foundation, the new supercomputer offers the potential to accelerate innovation in drug discovery.

The partnership will use ViaNautis’ proprietary polyNaut technology platform to develop genetic medicines that can precisely target tissue types.

Webinar Date/Time: Fri, Nov 22, 2024 11:00 AM EST